Credit: Getty Images New research is being conducted on factor XI inhibitor therapy as the patent expiration for factor Xa inhibitors nears. Factor XI inhibitor therapy research is being conducted as ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treatment with ...

This growth has come with a related increase in the incidence of hospital admissions and deaths related to bleeding, the major complication of anticoagulation. In 2017, there were approximately ...

Andexanet alfa (Andexxa; AstraZeneca), compared with usual care, improves hemostasis in patients who have an intracranial bleed while taking a factor Xa inhibitor, according to top-line results of ...

WILMINGTON, Del.--(BUSINESS WIRE)--ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of ANDEXXA (andexanet alfa) in patients on oral FXa inhibitor treatment including ...

Please provide your email address to receive an email when new articles are posted on . AstraZeneca announced a postmarketing trial assessing safety and efficacy of andexanet alfa stopped early due to ...

"[...] this is the first study to address the effects of Xa-Is on composite cardiovascular events, congestive heart failure, arteriosclerotic disease, and ...

Please provide your email address to receive an email when new articles are posted on . AIMS65 score predicted mortality and rebleeding for patients on anticoagulants with gastrointestinal bleeding.

A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...

Factor Xa inhibitors used to treat and prevent thrombotic events may cause or worsen acute major bleeding. New data suggest that bleeding episodes associated with factor Xa inhibitors may be treatable ...